Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.141
Filtrar
2.
J Eur Acad Dermatol Venereol ; 33 Suppl 5: 3-12, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31536168

RESUMO

BACKGROUND: The frequency of dermatological procedures is steadily increasing, accompanying a growing demand from patients. Chemical peels are a method of resurfacing in the treatment of various skin conditions. However, during the early healing process, patients may impose downtime on themselves. The erythema, pain and poor aesthetic appearance of the skin can lead to unwillingness to participate in social or professional activities. OBJECTIVES: The objective of this study was to evaluate the tolerance and efficacy of a repair cream based on Rhealba Oat plantlets extract and active healing compounds after a peeling procedure. METHODS: Men and women, aged 18-65 years, with Fitzpatrick phototype I-IV, who had previously received a medium-depth chemical peel on the face (TCA 30%) entered with their consent a clinical study evaluating the new test product based on Rhealba Oat and active healing compounds. At the beginning of the study, the selected patients received a TCA 30% medium-depth peel. Afterwards, they were treated during 29 days with the repair cream and evaluated for the benefits to downtime and pain. RESULTS: Significant reductions of pain (P < 0.0114) and erythema (P < 0.0001) were observed in the study. The downtime reduction with the tested cream was 92% - from 9 days after the previous peeling procedure to 0.74 days with application of the tested cream - a difference of 8.39 days. CONCLUSION: In consequence, the tested repair cream based on Rhealba Oat plantlets extract and active healing compounds brings clinical benefit to patients who undergo peeling procedures. By reducing pain and downtime, it allows patients to get back to their daily life activities a week earlier than with previous peels.


Assuntos
Avena/química , Abrasão Química , Eritema/tratamento farmacológico , Extratos Vegetais/uso terapêutico , Cicatrização/efeitos dos fármacos , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pomadas
3.
J Cosmet Dermatol ; 18(4): 1020-1024, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31169354

RESUMO

BACKGROUND: There are many postprocedure skin care options, but no consensus on the best formulation to optimize healing. Silicone gels have only been used to treat keloids and hypertrophic scars and typically applied after the wound has healed. This study compared the healing response after fractional ablative erbium laser resurfacing with a petrolatum-based ointment and a silicone gel. METHODS: A randomized, open-label, split-face study was performed. Ten subjects underwent Erbium:YAG (Sciton) fractional laser resurfacing. Patients were randomized to apply a petrolatum-based gel or a silicone gel (Stratacel® ; Stratpharma) on either the right or left side of the face. Subjects applied the products twice a day for 7 days and were evaluated in person 7, 30, and 60 days postprocedure. Subjects reported on the overall general aesthetic outcome, perceived pain, itch, and tightness via questionnaires using the Global Aesthetic Improvement Scale and the Wrinkle Severity Rating Scale (WSRS). RESULTS: All subjects healed without complications. By day 60, there was no difference in signs and symptoms of healing between the two different dressing approaches. However, patients treated with the silicone gel had less post-treatment erythema and hyperpigmentation. CONCLUSIONS: A novel silicone gel resulted in reduced signs of erythema and hyperpigmentation postprocedure, without an increase in adverse events. Additionally, the silicone gel dries to form a thin, full contact film and can be covered with sunscreen or cosmetics once dry. This new silicone gel presents a good option for postprocedure care after ablative fractional laser resurfacing.


Assuntos
Técnicas Cosméticas/efeitos adversos , Terapia a Laser/efeitos adversos , Vaselina/administração & dosagem , Géis de Silicone/administração & dosagem , Cicatrização/efeitos dos fármacos , Administração Cutânea , Adulto , Idoso , Bandagens , Eritema/tratamento farmacológico , Eritema/etiologia , Estética , Face , Feminino , Humanos , Hiperpigmentação/tratamento farmacológico , Hiperpigmentação/etiologia , Terapia a Laser/instrumentação , Lasers de Estado Sólido/efeitos adversos , Pessoa de Meia-Idade , Rejuvenescimento , Envelhecimento da Pele , Resultado do Tratamento
4.
J Drugs Dermatol ; 18(6): 503, 2019 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-31251541

RESUMO

With all the literature and research we have on acne and rosacea, there are still many unanswered questions. Over time, as we uncover more information on both preexisting and newly recognized pathophysiologic pathways, modes of drug action, alternative therapies, caveats related to basic skin care, and the potential roles for physical modalities, we often find that specific information that we thought was fact, is later altered, expanded, or corrected. What is interesting, and sometimes perplexing to me personally, is how difficult it is for the clinical dermatology community at large to incorporate well-published concepts into everyday clinical practice.


Assuntos
Fármacos Dermatológicos/uso terapêutico , Eritema/tratamento farmacológico , Rosácea/tratamento farmacológico , Fármacos Dermatológicos/farmacologia , Eritema/etiologia , Face , Humanos , Rosácea/etiologia , Pele/efeitos dos fármacos
5.
Indian J Pharmacol ; 51(2): 116-119, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31142947

RESUMO

OBJECTIVES: Dermatophytic infections are the common fungal infections aggravated by hot and humid climate. Terbinafine and itraconazole are commonly used oral antifungal agents for the same. However, resistance to these drugs is being seen increasingly when used in the conventional doses and duration. Therefore, this study was designed to compare the efficacy of terbinafine and itraconazole in increased dosages and duration in the treatment of tinea corporis and tinea cruris. MATERIALS AND METHODS: In this randomized comparative study, patients of tinea cruris and tinea corporis were randomly divided into two groups of 160 each and were given oral terbinafine (Group I) and oral itraconazole (Group II) for 4 weeks. The scores and percentage change in scores of pruritus, scaling, and erythema were evaluated at 2 and 4 weeks. RESULTS: At the end of week 4, mycological cure was seen in 91.8% after 4 weeks in the itraconazole group as compared to 74.3% of patients in the terbinafine group. There was a significant improvement in percentage change in pruritus, scaling, and erythema in both the groups from 0 to 4 weeks. On comparing groups, the percentage change was significantly different in scaling from 0 to 2 weeks (5.4 vs. -4.8) and 2-4 weeks (16.7 vs. 29.6) between Group I and Group II, respectively. Clinical global improvement was better with itraconazole. Mild adverse effects such as gastrointestinal upset, headache, and taste disturbances were observed which were comparable in both the groups. CONCLUSIONS: Itraconazole and terbinafine seem to be equally effective and safe in the treatment of tinea cruris and tinea corporis.


Assuntos
Antifúngicos/uso terapêutico , Itraconazol/uso terapêutico , Terbinafina/uso terapêutico , Tinha/tratamento farmacológico , Administração Oral , Adulto , Eritema/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prurido/tratamento farmacológico , Resultado do Tratamento , Adulto Jovem
6.
Korean J Gastroenterol ; 73(5): 285-293, 2019 May 25.
Artigo em Coreano | MEDLINE | ID: mdl-31132835

RESUMO

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract with an unknown etiology and pathogenesis. The incidence and prevalence of IBD are increasing rapidly in Korea. Approximately one-third of patients with IBD appear to develop extra-intestinal manifestations with the skin being one of the most commonly affected organs. They may precede, occur simultaneously, or follow the diagnosis of IBD. In addition, they may parallel with the luminal symptoms or independent from the disease activity of IBD. This review outlines the skin manifestations associated with IBD and discusses their management. Skin manifestations should be managed in close collaboration with a dermatologist.


Assuntos
Doenças Inflamatórias Intestinais/patologia , Dermatopatias/patologia , Eritema/complicações , Eritema/tratamento farmacológico , Eritema/patologia , Humanos , Imunossupressores/uso terapêutico , Doenças Inflamatórias Intestinais/complicações , Periodontite/complicações , Periodontite/patologia , Psoríase/complicações , Psoríase/patologia , Pioderma Gangrenoso/complicações , Pioderma Gangrenoso/tratamento farmacológico , Pioderma Gangrenoso/patologia , Dermatopatias/complicações , Esteroides/uso terapêutico , Síndrome de Sweet/complicações , Síndrome de Sweet/patologia
7.
Biol Pharm Bull ; 42(5): 728-735, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31061314

RESUMO

Dendrobium officinale protocorms (DOPs) are a specific developmental stage of Dendrobium officinale KIMURA et MIGO, which is used in folk medicine to ease skin issues, such as wrinkles and erythema. The purpose of the current study was to evaluate the effect of DOPs on UV irradiation-induced skin damage in bc_nu hairless mice, using matrixyl as a positive control. Hairless mice were randomly separated into 6 groups (8 mice per group). The normal control group received solvent and was not exposed to UV irradiation, while the model control group received solvent and was exposed to UV irradiation. The positive control group was subjected to UV irradiation and then received a 10 mg/mL formulation of matrixyl. The DOPs-treated groups received a transdermal application of a DOPs formulation after 4 weeks of UV irradiation. Relevant indicators, such as catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), thiobarbituric acid reactive substances (TBARS) and matrix metalloproteinases (MMPs), were then used to evaluate the ability of DOPs to repair photodamage. The results indicated that DOPs significantly reduced erythema and protected the skin from dryness and therefore exhibits a significant anti-photoaging effect. In addition, the expression of CAT, SOD, and GSH-Px increased while TBARS and MMPs levels decreased in DOPs-treated mice. This demonstrated that DOPs can inhibit photodamage in the skin of hairless mice. DOPs could be used as a potential therapeutic agent to protect the skin against UV-induced photoaging.


Assuntos
Dendrobium , Fármacos Dermatológicos/uso terapêutico , Protetores contra Radiação/uso terapêutico , Envelhecimento da Pele/efeitos dos fármacos , Raios Ultravioleta/efeitos adversos , Animais , Catalase/metabolismo , Eritema/tratamento farmacológico , Eritema/metabolismo , Glutationa Peroxidase/metabolismo , Masculino , Metaloproteinases da Matriz/metabolismo , Camundongos Pelados , Fitoterapia , Pele/efeitos dos fármacos , Pele/metabolismo , Superóxido Dismutase/metabolismo , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
9.
J Dermatol ; 46(6): 535-539, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31021010

RESUMO

Pegylated liposomal doxorubicin (PLD) is an anthracycline anticancer agent used in ovarian cancer and a form of doxorubicin enclosed in pegylated liposomes. There are only a few reports on intertrigo-like eruptions caused by PLD. We describe the first case of severe bullous erythema, including intertrigo-like eruptions with angioedema, induced by PLD in Japan. We present the case of a 53-year-old woman who was diagnosed with stage IIIC ovarian cancer. After receiving three cycles of PLD, the patient developed swelling of the upper lip and painful erythema with blisters and erosions on the axilla, upper back, flank and wrists. The patient was diagnosed with angioedema and severe skin lesions, including intertrigo-like eruptions induced by PLD. Although treatment with oral prednisolone and topical steroids was effective against these eruptions, the administration of PLD was discontinued because of its ineffectiveness against the primary disease. Several risk factors, such as obesity, perspiration and racial differences, may contribute toward a severe manifestation such as that seen in our patient. Moreover, our case was the first accompanied by angioedema. The mechanism of coexistence of intertrigo-like eruptions and angioedema is not clear; further studies are required to clarify the pathological mechanism of intertrigo-like eruptions.


Assuntos
Antibióticos Antineoplásicos/efeitos adversos , Doxorrubicina/análogos & derivados , Erupção por Droga/etiologia , Prednisolona/administração & dosagem , Administração Oral , Angioedema/induzido quimicamente , Angioedema/diagnóstico , Angioedema/tratamento farmacológico , Angioedema/patologia , Vesícula/induzido quimicamente , Vesícula/diagnóstico , Vesícula/tratamento farmacológico , Vesícula/patologia , Doxorrubicina/efeitos adversos , Erupção por Droga/diagnóstico , Erupção por Droga/tratamento farmacológico , Erupção por Droga/patologia , Eritema/induzido quimicamente , Eritema/diagnóstico , Eritema/tratamento farmacológico , Eritema/patologia , Feminino , Humanos , Intertrigo/induzido quimicamente , Intertrigo/diagnóstico , Intertrigo/tratamento farmacológico , Intertrigo/patologia , Pessoa de Meia-Idade , Neoplasias Ovarianas/tratamento farmacológico , Polietilenoglicóis/efeitos adversos , Pele/efeitos dos fármacos , Pele/patologia , Resultado do Tratamento
10.
Pak J Pharm Sci ; 32(1(Supplementary)): 293-300, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30829206

RESUMO

Pyrus communis fruit is traditionally used for improving the skin color and texture. The current study was designed to investigate Pyrus communis fruit phytoconstituents and their in-vivo rejuvenation effects on human skin by developing a stable emulgel formulation. Hydro-alcoholic extract of Pyrus communis was subjected to phytochemical analysis (TPC, TFC, antioxidant activity and anti-tyrosinase activity). A stable emulgel formulation loaded with 5% (w/w) Pyrus communis fruit extract was developed. Afterwards, this stable emulgel formulation was tested for effects on skin parameters and compared these with placebo (without fruit extract) by employing them on healthy human volunteers (n=13) for 3 months. Investigated in-vivo skin parameters were skin erythema, melanin, moisture, sebum and elasticity. Pyrus communis fruit extract showed excellent antioxidant and anti-tyrosinase activities. The developed formulation was stable in varying conditions of temperature and humidity for a period of 12 weeks. The active formulation showed statistically significant (p<0.05) decrease in skin melanin, erythema and sebum level while increase in skin elasticity and moisture content when compared with placebo. From findings it is concluded that Pyrus communis fruit extract loaded emulgel possesses antiaging potential with improvement in skin tone and elasticity, ameliorated skin moisture and showed skin whitening potential.


Assuntos
Emulsões/química , Extratos Vegetais/farmacologia , Pyrus/química , Pele/efeitos dos fármacos , Fator de Proteção Solar , Adulto , Antioxidantes/farmacologia , Emulsões/farmacologia , Eritema/tratamento farmacológico , Feminino , Flavonoides/análise , Géis/farmacologia , Humanos , Melaninas/metabolismo , Fenóis/análise , Compostos Fitoquímicos/química , Compostos Fitoquímicos/farmacologia , Extratos Vegetais/química , Rejuvenescimento , Sebo/efeitos dos fármacos
11.
Dermatol Surg ; 45(9): 1155-1162, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-30730346

RESUMO

BACKGROUND: Botulinum toxin (BTX) has been used cosmetically with good clinical efficacy and tolerable safety. OBJECTIVE: This randomized, double-blind, split-face clinical study aimed to investigate the efficacy and safety of intradermal BTX in patients with rosacea. MATERIALS AND METHODS: Twenty-four participants were enrolled and randomly given intradermal injections of BTX and normal saline in both cheeks. Clinician Erythema Assessment (CEA) score, Global Aesthetic Improvement Scale (GAIS) score, skin hydration, transepidermal water loss (TEWL), melanin content, erythema index, elasticity, and sebum secretions were evaluated at baseline and 2, 4, 8, and 12 weeks. RESULTS: On the BTX-treated side, the CEA score significantly decreased and the GAIS score significantly increased. The erythema index decreased at Weeks 4 and 8. Skin elasticity was improved at Weeks 2 and 4 and skin hydration, at Weeks 2, 4, and 8. However, TEWL and sebum secretion did not show significant differences. CONCLUSION: Intradermal BTX injections reduced erythema and rejuvenated the skin effectively and safely in patients with rosacea.


Assuntos
Toxinas Botulínicas Tipo A/administração & dosagem , Eritema/tratamento farmacológico , Eritema/fisiopatologia , Dermatoses Faciais/tratamento farmacológico , Dermatoses Faciais/fisiopatologia , Fármacos Neuromusculares/administração & dosagem , Rosácea/tratamento farmacológico , Rosácea/fisiopatologia , Adulto , Toxinas Botulínicas Tipo A/efeitos adversos , Método Duplo-Cego , Elasticidade , Estética , Feminino , Humanos , Injeções Intradérmicas , Masculino , Pessoa de Meia-Idade , Fármacos Neuromusculares/efeitos adversos , Projetos Piloto , Rejuvenescimento , Sebo/metabolismo , Pele/fisiopatologia
13.
J Dermatolog Treat ; 30(7): 703-707, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30663445

RESUMO

Background: Ivermectin (IVM) 1% cream represents an emerging therapy for papulo-pustular rosacea (PPR) and erythema-directed photography is a useful tool for evaluation of patient's erythema. Objective: The aim of our study was to assess the efficacy of IVM in PPR in achieving clear status at 8 weeks or at 20 weeks followed by respectively 24 and 12 weeks follow-up, using clinical/instrumental evaluation. Methods: Twenty patients with PPR were instructed to apply IVM for 8 weeks. At week 8, in case of complete response the therapy was stopped and a follow-up period up to 24 weeks was carried out, whereas in case of improvement the treatment was extended for additional 12 weeks followed by a 12 weeks follow-up. Instrumental evaluation was performed by erythema-directed digital photography (VISIA-CRTM- RBXTM). Results: At week 8, complete response was observed in 31.6% of cases along with a significant decrease of erythema degree. During treatment extension, additional improvement in terms of complete response, respectively at 12 (42%), 16 (47%) and 20 (58%) weeks, and reduction of erythema degree was observed. Conclusions: IVM is a valuable therapeutic option in mild/moderate PPR. Erythema-directed digital photography enhances erythema changes visualization compared to clinical observation alone.


Assuntos
Eritema/tratamento farmacológico , Ivermectina/uso terapêutico , Rosácea/tratamento farmacológico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Eritema/diagnóstico por imagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pomadas/uso terapêutico , Fotografação , Estudos Prospectivos , Rosácea/diagnóstico por imagem , Adulto Jovem
14.
Cell Death Dis ; 10(1): 19, 2019 01 08.
Artigo em Inglês | MEDLINE | ID: mdl-30622245

RESUMO

Ultraviolet radiation is markedly increased because of pollution and the depletion of the stratospheric ozone layer. Excessive exposure to sunlight can negatively affect the skin, resulting in sunburn, photo-aging, or skin cancer. In this study, we first determined the photoprotective effect of sanshool, a major component in Zanthoxylum bungeanum, on UVB-irradiated responses in human dermal fibroblasts (HDFs) and nude mouse. We found that sanshool treatment can protect cells against the effects of UVB irradiation by (i) increasing cell viability, (ii) inhibiting MMP expression, and (iii) inducing autophagy. We also used the recombinant CSF2 or anti-CSF2 antibody co-cultured with human dermal fibroblasts (HDFs) and found that CSF2 contributes to sanshool-induced autophagy. Sanshool hindered the UVB-induced activation of JAK2-STAT3 signaling in HDFs, thereby inhibiting the expression of MMPs and activation of autophagic flux. Exposure of the dorsal skin of hairless mice to UVB radiation and subsequent topical application of sanshool delayed the progression of skin inflammation, leading to autophagy and inhibiting the activation of JAK2-STAT3 signaling. These results provide a basis for the study of the photoprotective effect of sanshool and suggest that it can be potentially used as an agent against UVB-induced skin damage in humans.


Assuntos
Amidas/farmacologia , Autofagia/efeitos dos fármacos , Fibroblastos/efeitos da radiação , Janus Quinase 2/metabolismo , Extratos Vegetais/farmacologia , Protetores contra Radiação/farmacologia , Fator de Transcrição STAT3/metabolismo , Pele/efeitos da radiação , Raios Ultravioleta/efeitos adversos , Amidas/uso terapêutico , Animais , Autofagia/efeitos da radiação , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Eritema/tratamento farmacológico , Eritema/etiologia , Feminino , Fibroblastos/metabolismo , Humanos , Janus Quinase 2/antagonistas & inibidores , Inibidores de Metaloproteinases de Matriz/farmacologia , Inibidores de Metaloproteinases de Matriz/uso terapêutico , Camundongos , Camundongos Nus , Extratos Vegetais/uso terapêutico , Protetores contra Radiação/uso terapêutico , Radiodermatite/tratamento farmacológico , Fator de Transcrição STAT3/antagonistas & inibidores , Transdução de Sinais/efeitos da radiação , Pele/metabolismo , Zanthoxylum/química
15.
J Dermatol Sci ; 93(1): 58-64, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30658871

RESUMO

BACKGROUND: Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown. OBJECTIVES: To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions. METHODS: Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by ß-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections. RESULTS: Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers. CONCLUSIONS: These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.


Assuntos
Toxinas Botulínicas Tipo A/farmacologia , Degranulação Celular/efeitos dos fármacos , Eritema/tratamento farmacológico , Mastócitos/efeitos dos fármacos , Rosácea/tratamento farmacológico , Inibidores da Liberação da Acetilcolina , Animais , Peptídeos Catiônicos Antimicrobianos/administração & dosagem , Peptídeos Catiônicos Antimicrobianos/imunologia , Biópsia , Toxinas Botulínicas Tipo A/uso terapêutico , Degranulação Celular/imunologia , Células Cultivadas , Modelos Animais de Doenças , Eritema/imunologia , Eritema/patologia , Humanos , Injeções Intradérmicas , Mastócitos/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Cultura Primária de Células , Rosácea/imunologia , Rosácea/patologia , Pele/citologia , Pele/imunologia , Pele/patologia , p-Metoxi-N-metilfenetilamina/farmacologia
20.
J Cosmet Dermatol ; 18(1): 236-241, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29707883

RESUMO

BACKGROUND: Ascorbic acid is a substance with confirmed anti-free-radical properties. It triggers the collagen synthesis, has a depigmenting effect and seals blood vessels. All these properties have a significant effect of the skin's appearance. The characteristic traits of capillary skin include telangiectasias as well as erythema, which might consolidate in the future, along with the feeling of burning and increased skin sensitivity. OBJECTIVES: Study and evaluation of selected parameters of capillary skin after the application of 5% vitamin C concentrate throughout the period of 6 weeks with the use of instrumental tests and questionnaires. METHODS: The research was conducted on a group of 30 women ranging from 30 to 60 years of age with capillary skin indicating visible signs of erythematous plaques. The concentrate was applied once a day. Analyses of skin conditions were conducted four times: before the launch of the research D(0), after two 2D(14), after four 4D(28), and after 6 D(42) weeks of application. The research was conducted with the use of Mexameter MPA equipment, which was used to measure changes in the intensity of erythematous plaques. The depth of wrinkles was measured by PRIMOS system (two times D0 and 6D(42). The research also used VISIA system which allowed to perform visual and numeral skin analyses. Each research was finalized with a questionnaire which provided a subjective evaluation of the examined product among participants. RESULTS: Significant reduction in erythema has been widely recorded. After 2 weeks, erythema dropped by 9%. After 4 weeks, it decreased by 16% and by 21% after 6 weeks. The concentrate's efficiency in diminishing erythematous plaques was confirmed by photographs generated by VISIA photograph system. Thanks to PRIMOS, decrease in both depth and volume of nasolabial folds was recorded in 87% of participants after 6 weeks of research. CONCLUSION: 5% vitamin C concentrate is effective in treating capillary and photograph-aging skin. It decreases erythema and telangiectasias as well as triggers the shallowing of skin wrinkles.


Assuntos
Antioxidantes/uso terapêutico , Ácido Ascórbico/uso terapêutico , Eritema/tratamento farmacológico , Dermatoses Faciais/tratamento farmacológico , Telangiectasia/tratamento farmacológico , Adulto , Antioxidantes/farmacologia , Ácido Ascórbico/farmacologia , Feminino , Humanos , Pessoa de Meia-Idade , Satisfação do Paciente , Envelhecimento da Pele/efeitos dos fármacos , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA